Immunoprecise Antibodies Ltd Share Price Toronto S.E.
Equities
TQY
CA87588T2020
Pharmaceuticals
Sales 2024 * | 2.46Cr 1.81Cr 150.78Cr | Sales 2025 * | 2.98Cr 2.19Cr 182.84Cr | Capitalization | 4.31Cr 3.17Cr 264.31Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.2Cr -88.24L -74Cr | Net income 2025 * | -90L -66.18L -55Cr | EV / Sales 2024 * | 1.75 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
-4.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/23/29 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/23/05 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
1st Jan change | Capi. | |
---|---|---|
-1.26% | 8.95TCr | |
+2.76% | 4.07TCr | |
-9.06% | 3.3TCr | |
+55.32% | 2.47TCr | |
-16.61% | 1.51TCr | |
-9.14% | 1.28TCr | |
-12.11% | 1.18TCr | |
-43.61% | 1.16TCr | |
+7.79% | 890.22Cr |